Tag: cardiovascular events

1. Risk of acute myocardial infarction and ischemic stroke was increased during the first two weeks following a COVID-19 infection compared to the general population. 2. The risk of developing acute myocardial infarction and ischemic stroke decreased in weeks 3-4 following a COVID-19 infection compared to the first two weeks. Evidence...
1. Widespread diabetes screening helps to identify asymptomatic patients with preserved renal function and low diabetes-associated cardiovascular risk. 2. New cardiovascular risk stratification strategies are needed given heterogeneous characteristics of patients with type 2 diabetes.  Evidence Rating Level: 2 (Good)  Study Rundown: In the last decade, New Zealand Ministry of Health has...
1. Older patients with polypharmacy who discontinued statins had increased rates of admissions for heart failure, all-cause emergency hospital admissions, cardiovascular outcomes, and all-cause death versus those that did not. Evidence Rating Level: 2 (Good) Study Rundown: With advanced age, patients have multiple comorbidities and are commonly treated with multiple drugs,...
1. Regardless of cardiovascular disease history and baseline blood pressure, a 5 mmHg reduction in systolic blood pressure reduced relative risk of major cardiovascular events by 10%. 2. These findings support considering antihypertensive medications for patients with increased cardiovascular risk, even those who are normotensive at baseline.  Evidence Rating Level: 1...
1. Vadadustat was shown to be non-inferior to darbepoetin alfa in cardiovascular safety for patients with anemia and dialysis-dependent chronic kidney disease (DD-CKD). 2. Vadadustat was shown to present comparable efficacy in normalizing hemoglobin concentration compared to darbepoetin alfa in the patient population. Evidence Rating Level: 1 (Excellent) Study Rundown: Chronic kidney...
1. Guided selection of antiplatelet therapy reduced rates of major adverse cardiovascular event rates compared to standard therapy. 2. Guided selection strategy was beneficial for both escalation and de-escalation of standard therapy, balancing patient-dependent ischemic and bleeding risks.  Evidence Rating Level: 1 (Excellent) Study Rundown: Patients who undergo percutaneous coronary intervention (PCI)...
1. Hospital readmission and mortality rates were higher in post-COVID patients as compared to matched control groups. 2. More diagnoses of respiratory disease, diabetes, and cardiovascular events were observed in post COVID patients. 3. Older and non-white individuals were at the highest risk for post-COVID complications. Evidence Rating Level: 2 (Good) Study Rundown:...
1. Polypill plus aspirin treatment was shown to decrease the incidence of cardiovascular events compared to placebo in patients without cardiovascular disease. 2. Adverse events such as hypotension and dizziness were shown to be higher in the polypill-only group compared to the placebo group. Evidence Rating Level: 1 (Excellent) Study Rundown: Polypills...
1. Combined use of intracoronary near-infrared spectroscopy (NIRS) and intravascular ultrasound were effective at detecting untreated intracoronary lesions at high risk of major adverse cardiac event (MACE). 2. Highly lipidic lesions and large plaque burden were found to be independent predictors of non-culprit lesion-related MACEs. Evidence Rating Level: 2 (Good) Study Rundown:...
1. The use of long-term transdermal estrogen for castration therapy for prostate cancer showed no difference in cardiovascular events versus current standard of care. 2. Gynecomastia was significantly more common in the transdermal estrogen group than standard of care group. Evidence Rating Level: 1 (Excellent) Study Rundown: Prostate cancer, an ongoing major...